Understanding Optimizing And Overcoming Resistance To Current Kras Inhibitors
If you are looking for information about Optimizing And Overcoming Resistance To Current Kras Inhibitors, you have come to the right place. Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the latest developments in
Key Takeaways about Optimizing And Overcoming Resistance To Current Kras Inhibitors
- Dr Mark Awad speaks to ecancer about the mechanisms of acquired
- This video explores groundbreaking clinical data on alisertib (also referred to as elisrasib), a highly potent
- Acquired
- Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, discusses the latest developments in ...
- Liza Villaruz, MD, University of Pittsburgh, Pittsburgh, PA, comments on the potential mechanisms of
Detailed Analysis of Optimizing And Overcoming Resistance To Current Kras Inhibitors
Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, provides an overview of treatment ... Please visit answersincme.com/860/120773-replay to participate, download slides and supporting materials, complete the post ... Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, describes
This video is part of the HMP Education content archive and may include previously accredited educational material. While this ...
We hope this detailed breakdown of Optimizing And Overcoming Resistance To Current Kras Inhibitors was helpful.
